Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Thyroid Neoplasms × lenvatinib × Clear all

Phase

Phase 2 6 Phase 4 3 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 19 Parkinson Disease 4, Autosomal Dominant Lewy Body 14 Carcinoma, Renal Cell 5 Squamous Cell Carcinoma of Head and Neck 2 Melanoma 2 Endometrial Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 von Hippel-Lindau Disease 1 Thyroid Neoplasms 1 Recurrence 1 Neoplasms 1 Liver Neoplasms 1 Kidney Neoplasms 1 Hematologic Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Transitional Cell 1 Advanced Malignancies 1 Advanced Endometrial Cancer 1

Interventions

Iodine-131 3 Thyrotropin Alfa 2 vandetanib 1 lenvatinib 1 fosbretabulin 1 combretastatin 1 cabozantinib 1 Thyroidectomy 1 Sorafenib 1 Ropivacaine 1 Radiotherapy 1 Paclitaxel 1 Neck Dissection 1 Metformin 1 Epinephrine 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01321554 2023-06-22

SELECT

Eisai Inc.

Phase 3 Completed

392 enrolled 10 charts

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡